Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Minnesota: - Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
- Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
- Fairview Ridges Hospital — Burnsville, Minnesota
- Mercy Hospital — Coon Rapids, Minnesota
- Essentia Health Cancer Center — Duluth, Minnesota
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07215910
Sites in Minnesota: - Mercy Hospital — Coon Rapids, Minnesota
- Fairview Southdale Hospital — Edina, Minnesota
- Abbott-Northwestern Hospital — Minneapolis, Minnesota
- Coborn Cancer Center at Saint Cloud Hospital — Saint Cloud, Minnesota
- Regions Hospital — Saint Paul, Minnesota
Phase 3 Recruiting Network
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …
Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in Minnesota: - Children's Hospitals and Clinics of Minnesota - Minneapolis — Minneapolis, Minnesota
- Mayo Clinic in Rochester — Rochester, Minnesota
Phase 3 Recruiting Network
Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT03550391
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota
- Regions Hospital — Saint Paul, Minnesota
Phase 3 Recruiting Industry
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05580562
Sites in Minnesota: - University of Minnesota — Minneapolis, Minnesota
- Mayo Clinic - Cancer Center - Rochester — Rochester, Minnesota
Phase 3 Recruiting Industry
This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) …
Sponsor: Nuvation Bio Inc.
NCT ID: NCT05303519
Sites in Minnesota: - Mayo Clinic - Rochester — Rochester, Minnesota
Phase 2, Phase 3 Recruiting Academic/Other
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and …
Sponsor: Global Coalition for Adaptive Research
NCT ID: NCT03970447
Sites in Minnesota: - Allina Health Systems/Abbott Northwestern Hospital — Minneapolis, Minnesota
- Mayo Clinic Cancer Center - Rochester — Rochester, Minnesota
Phase 3 Recruiting Industry
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together…
Sponsor: NovoCure GmbH
NCT ID: NCT06556563
Sites in Minnesota: - Masonic Cancer Center, University of Minnesota — Minneapolis, Minnesota
- Mayo Clinic - Rochester — Rochester, Minnesota
Phase 3 Recruiting Industry
The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also imper…
Sponsor: CarThera
NCT ID: NCT05902169
Sites in Minnesota: - Mayo Clinic Rochester — Rochester, Minnesota
Phase 3 Recruiting Academic/Other
This phase III trial studies the side effects and how well stereotactic radiosurgery (SRS) works before or after surgery in patients with tumors that has spread to the brain or that can be removed by surgery. Stereotactic radiosurgery is a…
Sponsor: Mayo Clinic
NCT ID: NCT03750227
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy versus the usual chemotherapy alone (temozo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05432804
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Minnesota: - University of Minnesota/Masonic Cancer Center — Minneapolis, Minnesota
Phase 1, Phase 2 Recruiting Academic/Other
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in Minnesota: - Masonic Cancer Center University of Minnesota — Minneapolis, Minnesota
Phase 1, Phase 2 Recruiting Industry
This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the secon…
Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT06810544
Sites in Minnesota: - Mayo Clinic Cancer Center — Rochester, Minnesota
Phase 2 Recruiting Academic/Other
This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib (arm is currently closed to accrual) * Temozolomide (temodar) * Neratinib (a…
Sponsor: David Reardon, MD
NCT ID: NCT02977780
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
Phase 1, Phase 2 Recruiting Industry
The purpose of the study is to determine the recommended dose and further understand the safety of MT-125 in participants who have been diagnosed with glioblastoma, a primary brain tumor, when administered in combination with your standard…
Sponsor: Myosin Therapeutics Inc.
NCT ID: NCT07185880
Sites in Minnesota: - Mayo Clinic Hospital — Rochester, Minnesota
Phase 2 Recruiting Academic/Other
This phase II trial compares the effect of adding WSD0922-FU to temozolomide versus temozolomide alone in slowing disease progression in patients with Epidermal Growth Factor Receptor (EGFR)-mutant, IDH-wildtype glioblastoma. Temozolomide …
Sponsor: Mayo Clinic
NCT ID: NCT07708961
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota
Phase 2 Recruiting Academic/Other
This phase II trial tests how well retifanlimab with bevacizumab and hypofractionated radiotherapy, compared to bevacizumab and hypofractionated radiotherapy alone, works in treating patients with glioblastoma that has come back after a pe…
Sponsor: Academic and Community Cancer Research United
NCT ID: NCT06160206
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
Phase 2 Recruiting Academic/Other
This phase II trial studies how well the addition of 18F-DOPA (amino acid) positron emission tomography (PET)/computed tomography (CT) to standard of care (SOC) imaging can improve the clinical management of patients with brain tumors in o…
Sponsor: Mayo Clinic
NCT ID: NCT06667726
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota
Phase 2 Recruiting Academic/Other
This phase II trial compares the effect of GI-102 alone and in combination with pembrolizumab given before surgery in treating patients with IDH wildtype glioblastoma and IDH mutated grade 4 astrocytoma that has come back after a period of…
Sponsor: Mayo Clinic
NCT ID: NCT07301268
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota
Phase 1 Recruiting Academic/Other
This phase I trial studies the side effects and best dose of trametinib and everolimus in treating pediatric and young adult patients with gliomas that have come back (recurrent). Trametinib acts by targeting a protein in cells called MEK …
Sponsor: University of California, San Francisco
NCT ID: NCT04485559
Sites in Minnesota: - Children's Minnesota — Minneapolis, Minnesota
Phase 1 Recruiting Industry
This is a phase I, open-Label, single/multiple dose, dose-escalation study to evaluate the safety, tolerability and antitumor activity of anti-B7-H3 CAR-T cell injection (TX103) in subjects with recurrent or progressive Grade 4 Glioma.The …
Sponsor: Tcelltech Inc.
NCT ID: NCT06482905
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota
EARLY Phase 1 Recruiting Academic/Other
This early phase I trial tests the safety, best dose, and effectiveness of SONALA-001 or 5-ALA HCL in combination with magnetic resonance imaging-guided focused ultrasound (MRgFUS), also called sonodynamic therapy, in treating patients wit…
Sponsor: Mayo Clinic
NCT ID: NCT07076472
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota
EARLY Phase 1 Recruiting Academic/Other
The purpose of this research is to evaluate the performance \[sensitivity, specificity, accuracy\] of FET PET/CT imaging to detect ACTH-secreting pituitary adenoma, using operative findings and histopathology as truth standard.
Sponsor: Mayo Clinic
NCT ID: NCT07460232
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota
Phase 1 Recruiting Academic/Other
The purpose of this study is to test WSD0628 in combination with radiation therapy for recurrent brain tumors.
Sponsor: Mayo Clinic
NCT ID: NCT05917145
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota